Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

Trial Profile

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Therapeutic Use
  • Acronyms SIGNATURE
  • Sponsors Array BioPharma; Novartis Pharmaceuticals
  • Most Recent Events

    • 23 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jul 2014 New source identified and integrated (M.D. Anderson Cancer Center: 2013-0864).
    • 04 Jun 2014 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top